

ersonal use only

Beamtree[®]

1H FY26 Results

February 2026

Authorised for release by the Board of Directors

Important Notice and Disclaimer

The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, February 2026.

This presentation may contain statements that are, or may be deemed to be, forward looking statements. Such statements can generally be identified by the use of words such as “believe”, “estimate”, “plan”, “target”, “project”, “anticipate”, “expect”, “intend”, “likely”, “may”, “will”, “could” or “should” and similar expressions. Indications of strategy, plans, objectives, targets, goals, future events or intentions are also forward-looking statements.

You should not place undue reliance on such forward-looking statements. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of BMT or any of its related entities which may cause actual results to differ materially from those expressed or implied in such statements.

No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation. Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

The information in the presentation is given for informational purposes only, is in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with BMT’s other announcements to ASX. It is not intended to be relied upon as advice to current shareholders, investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation is made as to the accuracy, completeness or reliability of the presentation.

The views expressed in this presentation may contain information that has been derived from publicly available sources that have not been independently verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information. Market share information is based on management estimates except where explicitly identified.

To the maximum extent permitted by law, BMT and any person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation, any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

BMT is not obliged to, and does not represent that it will, update the presentation for future developments. All currency figures are in Australian dollars unless otherwise stated. Totals may not add up precisely due to rounding.

Agenda



Overview



1H FY26 financial highlights



AI competitive moat



Progress against strategy



Pipeline



1H FY26 financial performance






Outlook

ersonal use only

Beamtree[®]

1H FY26 Financial Highlights

1H FY26 Financial Highlights

<p>↑ 10% PcP*</p>	<p>↑ 10% PcP</p>	<p>Break Even Operating Profit</p>	<p>Positive Operating Cashflow</p>	<p>\$2.9M</p>
 <p>Annual Recurring Revenue (ARR)</p>	 <p>Recurring Revenue</p>	 <p>Operating Profit</p>	 <p>Operating Cash Flow</p>	 <p>Cash</p>
<p>\$28.0M</p>	<p>\$13.5M</p>	<p>\$0.1M</p>	<p>\$0.4M</p>	<p>Strong liquidity with \$4.3M undrawn Debt Facility</p>

* PcP refers to the Prior Corresponding Period (i.e., 1H FY25). 1H FY25 exit ARR was \$25.5M.

AI Competitive Moat

Deep customer relationships

- Trust
- ROI track record
- High bar for accuracy



Extensive domain expertise

- Operational and clinical hospital data going back decades
- Standards and degrees of complexity which differ by geography



AI 'native'

- AI deployed in product suite going back decades (Rippledown)
- Existing and new products



- Evolve
 - Autonomous Coding
 - Autonomous Data Entry
- Built on AI**




Highly regulated environment

- IHACPA, AIHW, HIMAA (Aus)
- SHC, MOH, CNHI, CHI, SCFHS, SHIMA (Saudi)
- CIHI, Health Canada, Provincial MoHs, CHIMA (Can)
- NHS England, NICE, ICBs, IHRIM (England)



Our Markets and Products



Product Co-development

ACS   

Evolve 

3 Strong Partners

KSA 

UK 

Global 

 **6**
Continents

 **+25**
Countries

 **+1,200+**
Locations

Progress against Strategy

- **Measurable benefits delivered to our customers**

 - Improved clinical decision-making and quality (6–8x ROI)

 - Coding accuracy (30% reduction in rework costs)

 - Reimbursement outcomes (up to 24x ROI)

- **Next generation data platform for the UK NHS (Evolve):**

 - Our next-generation analytics and benchmarking platform has completed user testing with four founder NHS Trusts and is now live – a milestone that positions us to scale across the broader NHS estate.

- **AI driven Autonomous Coding Solution:**

 - We have successfully completed our Australian trial and are progressing trials in the UK and Canada, where Canada's first public sector RFP is now underway. This validates both the product and our ability to open new international markets.


- **Integrated Coding Platform live in Saudi Arabia:**

 - POCs are live across three public hospital clusters in Saudi Arabia, and we have appointed a new GM Sales (Middle East) to accelerate in-country conversion alongside our partner, Lean.

- **Strengthened Go-to-Market Capability:**

 - We have appointed a new GM Sales (ANZ) to strengthen commercial execution, and our new CFO brings experience and capability to scale our operational infrastructure.

\$24m late-stage opportunities in pipeline



* Late-stage pipeline refers to deals where we are engaged with customers in the contracting process. Contracting processes are complex in nature in regulatory healthcare with extended execution timeframes.

ersonal use only


Beamtree[®]

1H FY26 Financial Performance

Revenue by Product Segment and Geography (\$'M)


Revenue by Product Segment

- Non-Recurring
- Knowledge Networks
- Clinical Decision Support
- Coding & Data Quality Assurance
- Diagnostic



Revenue by Geography

- ANZ
- INTL
- Non-Recurring



Profit and Loss (\$'M)

	1H FY25	1H FY26	Growth on PcP
Recurring Revenue	12.3	13.5	10%
Diagnostic	3.7	4.0	8%
Coding & data quality assurance	2.8	3.4	21%
Clinical decision support	0.2	0.1	(50%)
Knowledge networks	5.6	6.0	8%
Non-Recurring Revenue	1.9	1.0	(46%)
Total Revenue	14.2	14.5	2%
Expenses – people	(10.7)	(10.9)	2%
Expenses – non people	(3.6)	(3.6)	(0%)
Total Operating Expenses	(14.2)	(14.5)	2%
Operating Profit/(Loss)	0.0	0.1	1124%
Capitalised development cost	1.1	2.0	82%
Cash Operating Profit/(Loss)	(1.1)	(2.0)	78%

Group Recurring Revenue

+10%

Operating Expenses

+2%

Break Even Operating Profit

\$0.1m

Continuing investment to strategic priorities and geographical expansion

\$2m (\$0.9M Evolve, now live)

Cash and Liquidity

	1H FY25	1H FY26	Variance
Cash flows from operating activities			
Receipts from customers (inclusive of GST)	15.1	16.8	
Payments to suppliers and employees (inclusive of GST)	(15.2)	(16.3)	
Interest received	0.0	0.1	
Interest and other finance costs paid	(0.0)	(0.1)	
Net cash from/(used in) operating activities	(0.0)	0.4	0.5
Cash flows from investing activities			
Payments for property, plant and equipment	(0.1)	(0.1)	
Payments for intangibles	(1.1)	(2.0)	
Net cash used in investing activities	(1.2)	(2.2)	(1.0)
Cash flows from financing activities			
Repayment of lease liabilities	(0.1)	(0.1)	
Net cash from/(used in) financing activities	(0.1)	(0.1)	(0.0)
Net increase/(decrease) in cash and cash equivalents	(1.3)	(1.8)	
Cash and cash equivalents at the beginning of the financial	5.0	4.8	
Cash and cash equivalents at the end of the financial	3.7	2.9	(0.8)

Positive Operating Cash Flow

Supported by effective working capital management

Continued Investment


To drive strategic priorities and geographical expansion

Cash on hand \$2.9m

With access to further \$4.3m via undrawn facility. Liquidity strong, supported by \$4.6M* Net Current Assets

* Net Current Assets (NCA) calculated as Current Assets (\$10M) less Current Liabilities excluding Contract Liabilities (\$5.4M) (NCA at 30-June-25: \$4.5M).

Simplifying ARR for Scale (\$M)



Expected churn of \$0.8M as the business continues to simplify for scale

Enterprise contract timing and extended procurement cycles, expected to convert in H2

Positioned to accelerate in H2 off clear ARR Baseline*

	Aug 25	Feb 26
Contracted Revenue	27.9	27.2
Verbal Commitments	0.4	0.8
Total ARR	28.3	28.0



* FY25 exit ARR has been restated from \$29.2M to exclude \$0.9M that did not convert to recurring revenue. Please note, ARR is measured at the announcement date, not financial period end, and includes both contracted and high confidence verbal customer commitments.

ersonal use only

Beamtree[®] FY26 Outlook



FY26 Outlook



Strategy and Team

All systems go! Continue to execute the strategy, and accelerate revenue growth

Strong team with new capabilities to drive scale

Defined market opportunity, with strong partners

Ongoing product innovation leveraging AI



Financial

Targeting accelerated double digit ARR growth for FY26 and committed to the business being self funded in the near term



Strategic Review

Board initiated strategic review to examine operational priorities and corporate options, including strategic partnerships

ersonal use only

Thank you

Beamtree®